The Board of Directors of Marcolin, on 28 March presented the draft of the Group's separate and consolidated financial statements for the year ended 31 December 2022, which will be subject to approval by the Shareholders' Meeting in April.
Results up to 31 December 2022
In 2022, Marcolin's net sales amounted to €547.4 million, up 20.1% compared to the previous year at current exchange rates (+ 13.2% at constant exchange rates), confirming the strength of the business strategy in a year marked by international geopolitical challenges and instability.
Compared to 2021, the Company has improved its performance in all geographical areas: significant growth in a high potential market such as Asia (+ 47% at current exchange rates and + 33% at constant exchange rates), while EMEA (+ 18% at current exchange rates and + 17% at constant exchange rates) and Americas (+ 17% at current exchange rates and + 4% at constant exchange rates) are confirmed as the main geographical areas, together accounting for approximately 90% of revenue.
Adjusted EBITDA reached €61.0 million, showing an increase of 21.7% compared to €50.1 million in the previous year. The trend in the adjusted EBITDA margin was positive as well, reaching 11.1% of net sales.
Various factors contributed to the achievement of these important results, including the consolidation of the numerous brands in the portfolio, the implementation of a digital transformation process based on the central role played by the relationship with customers in all its phases, and the continuous push towards production and procurement efficiency.
The net financial position amounted to €137.4 million, an improvement of €10.7 million compared to the previous year, thanks to the liquidity generated by both operating results and a regulated control of working capital in all its components (trade receivables, trade payables and inventory levels).
Marcolin and sustainability
In 2022, Marcolin also gave further impetus to its commitment to sustainability and ESG issues through numerous corporate governance development actions including, as example, obtaining the ISO 13485 certification, which regulates quality management systems in the medical device sector internationally.
